(Q34526397)

2 August 2017

1 reference

title

Bcl-2 clearance: optimising outcomes in follicular non-Hodgkin's lymphoma (English)

1 reference

2 August 2017

Berinstein NL

1

1 reference

2 August 2017

Buckstein R

2

1 reference

2 August 2017

Imrie K

3

1 reference

2 August 2017

Spaner D

4

1 reference

2 August 2017

Mangel J

5

1 reference

2 August 2017

Tompkins K

6

1 reference

2 August 2017

Pennell N

7

1 reference

2 August 2017

Reis M

8

1 reference

2 August 2017

Pavlin P

9

1 reference

2 August 2017

Lima A

10

1 reference

2 August 2017

Couvadia A

11

1 reference

2 August 2017

Robinson J

12

1 reference

2 August 2017

Richardson P

13

1 reference

2 August 2017

language of work or name

English

0 references

publication date

1 February 2002

1 reference

Bone Marrow Transplantation

2 August 2017

published in

1 reference

2 August 2017

volume

29 Suppl 1

1 reference

2 August 2017

page(s)

S14-7

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bmt.1703297

2 August 2017

exact match

0 references

cites work

A pilot study on the use of the ProMACE-CytaBOM regimen as a first-line treatment of advanced follicular non-Hodgkin's lymphoma. Gruppo Italiano per lo Studio dei Linfomi.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703297

BCL2 translocation frequency rises with age in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703297

BCL-2 family: regulators of cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703297

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703297

Clearing of cells bearing the bcl-2 [t(14;18)] translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703297

Purging peripheral blood progenitor cell grafts from lymphoma cells: quantitative comparison of immunomagnetic CD34+ selection systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703297

Autologous stem-cell transplantation for non-Hodgkin's lymphomas: the role of graft purging and radiotherapy posttransplantation--results of a retrospective analysis on 120 patients autografted in a single institution.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703297

Investigation of monoclonal antibody therapy with conventional and high-dose treatment: current clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703297

Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703297

The natural history of initially untreated low-grade non-Hodgkin's lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703297

inferred from DOI database lookup

7 January 2021

based on heuristic

Detection of occult lymphoma in the peripheral blood and bone marrow of patients with untreated early-stage and advanced-stage follicular lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703297

inferred from DOI database lookup

7 January 2021

based on heuristic

Molecular response assessed by PCR is the most important factor predicting failure-free survival in indolent follicular lymphoma: update of the MDACC series

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703297

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/SJ.BMT.1703297

1 reference

Dimensions Publication ID

2 August 2017

1001387792

0 references

1 reference